The Bull Rankings scorecard — our quality-growth score is 78 / 100, built from three pillars each graded 0–100 against sector peers: Quality 77, Growth 91, Value 68. At today's price, our reverse-DCF read says the market is implicitly betting on about 13% a year in free-cash-flow growth sustained for a decade — a gauge of how much optimism is already in the stock.
The thesis
The Bull Rankings model gives Veeva a 78/100 quality‑growth score, with growth as the strongest pillar at 91 and value the weakest at 68. That split tells the story: this is a compounder built to keep printing cash, but the market isn’t paying for safety. Revenue grew 16.2% in the fiscal year ended April 30 2026, while free cash flow hit $1.7 billion in the trailing twelve months, a figure that puts the company’s cash‑generation power on full display. The stock trades at 43 times trailing earnings, a multiple that only makes sense if the growth is durable and the moat is deep. Our model’s reverse DCF says today’s price assumes roughly 13% annual free‑cash‑flow growth for a decade — a number that towers over the 16.2% revenue growth and signals the market is betting on more than just the status quo. Either Veeva keeps expanding its Commercial Cloud footprint in life sciences, or the premium evaporates.
What the business actually is
Veeva sells cloud software exclusively to the life sciences industry, a niche that shields it from the distractions of broader enterprise software. Its Commercial Cloud is the crown jewel: Veeva Vault CRM Suite keeps pharmaceutical and biotech sales teams coordinated, Veeva Medical curates medical content across channels, and Veeva PromoMats manages digital assets end‑to‑end. The company also layers in data infrastructure with Veeva Data Cloud, including Veeva OpenData for customer reference data and Veeva Link for deep analytics. Every product line is built for regulated environments, a constraint that turns compliance into a competitive advantage because switching costs are high and validation cycles are long.
Why it can keep compounding
The durability signal is the 28.4% profit margin in the quarter ended April 30 2026, a figure that shows how little capital Veeva needs to reinvest to keep growing. Return on equity sits at 12.9%, modest by software standards but respectable given the industry’s capital‑light model. The moat isn’t just the software stack; it’s the data layer that makes each customer’s content and reference more valuable the longer they stay. A competitor would need to replicate not only the software but also the validated data network and the industry‑specific workflows, a feat that takes years and regulatory approvals. Our model flags this as a durable high‑return franchise, and the numbers back it up.
The valuation question
At $242.75, Veeva’s multiple of 43 times earnings already prices in a lot of future growth. The Bull Rankings model’s reverse DCF implies the stock needs roughly 13% annual free‑cash‑flow growth for the next decade to justify today’s price. That’s a steep hurdle when revenue grew 16.2% in the latest fiscal year, and the gap between 13% implied growth and 16.2% actual growth suggests the market is assuming margin expansion or buybacks to bridge the difference. The debt‑to‑equity ratio of 0.01 shows the company can fund buybacks without leverage, but the math still requires the growth engine to keep firing. If the Commercial Cloud’s expansion slows, the premium quickly looks rich.
The bear case
The weakest pillar in the Bull Rankings model is value at 68, and the skeptic’s lever is the P/E itself. At 43 times trailing earnings, Veeva is expensive relative to the broader market, and the model’s implied growth of 13% per year for a decade is optimistic given the 16.2% revenue growth in the fiscal year ended April 30 2026. If life‑sciences spending tightens or a competitor cracks the regulatory moat, the multiple could compress fast. The stock’s 52‑week range of $148.05 to $310.50 shows how much air can come out when sentiment shifts.
What would change our mind
The first falsifiable condition is revenue growth slipping below 12% in a fiscal year. The second is free‑cash‑flow growth falling short of the 13% implied by our model. The third is a sustained compression in the P/E below 30 times earnings, which would tell us the market no longer believes the growth is worth the premium. Watch those three lines — they’re the only ones that matter.